Identification of RCC1- LCK as a novel fusion gene in pediatric
erythroid sarcoma
- Satoru Oya,
- Shinya Osone,
- Masanori Yoshida,
- Sota Nishimoto,
- Yoshihiro Taura,
- Hideki Yoshida,
- Mitsuru Miyachi,
- Tohru Inaba,
- Eiichi Konishi,
- Motohiro Kato,
- Toshihiko Imamura,
- Tomoko Iehara
Satoru Oya
Kyoto Prefectural University of Medicine School of Medicine Graduate School of Medical Science
Corresponding Author:[email protected]
Author ProfileShinya Osone
Kyoto Prefectural University of Medicine, Graduate School of Medical Science
Author ProfileMasanori Yoshida
National Center for Child Health and Development
Author ProfileYoshihiro Taura
Kyoto Prefectural University of Medicine School of Medicine Graduate School of Medical Science
Author ProfileToshihiko Imamura
Kyoto Prefectural University of Medicine
Author ProfileAbstract
Erythroid sarcoma is very rare form of pure erythroid leukemia with
undetermined biological features. Here, we present an infant with a
multifocal erythroid sarcoma, diagnosed because the tumor cells were
positive for glycophorin A. After acute myeloid leukemia-oriented
chemotherapy and surgical resection followed by cord blood
transplantation, he has successfully maintained complete remission
without any late effects. Total transcriptome analysis of the tumor
identified a novel fusion gene, RCC1-LCK, and high LCK expression
levels, suggesting that LCK overexpression was involved in
leukemogenesis in this case.10 Apr 2022Submitted to Pediatric Blood & Cancer 10 Apr 2022Submission Checks Completed
10 Apr 2022Assigned to Editor
15 Apr 2022Reviewer(s) Assigned
03 May 2022Review(s) Completed, Editorial Evaluation Pending
05 May 2022Editorial Decision: Revise Major
27 May 2022Submission Checks Completed
27 May 2022Assigned to Editor
27 May 20221st Revision Received
30 May 2022Review(s) Completed, Editorial Evaluation Pending
30 May 2022Editorial Decision: Accept